Patent settlements

Abuse of dominance, European Court of Justice, European Union, Market definition, Patent settlements, Pharmaceuticals

(Geradin Partners)/ /Leave a comment

On 27 June 2024, the EU Court of Justice (“CJEU”) issued its judgments in the Perindopril (Servier) case. The judgments follow a European Commission (“EC”) decision of 9 July 2014, and a series of General Court (“GC”) judgments of 12 December 2018 in relation to appeals against that EC decision. The case started with a…

Ex ante regulation, Ex ante regulatory assessment, Ex post regulatory assessment, India, Intellectual property (IP), National competition authorities (NCAs), Patent settlements

, , (Fox & Mandal)/ /Leave a comment

The Honorable Delhi High Court has recently in the case of Telefonaktiebolaget LM Ericsson (PUBL) v. Competition Commission of India held that when a patent is issued in India, the Competition Commission of India (CCI) cannot inquire into the actions of a patentee in the exercise of its power under the Competition Act, 2002. The…

Abuse of dominance, European Commission, Patent settlements, Pharmaceuticals

(Allen & Overy)/ /Leave a comment

On 10 October 2022, the European Commission (EC) sent a Statement of Objections to Teva Pharmaceutical Industries Limited and Teva Pharmaceuticals Europe BV (Teva). The EC has provisionally found that Teva abused its dominant position in the market for the treatment of multiple sclerosis by misusing patent procedures and engaging in a disparagement campaign. This is not…

Abuse of dominance, Interim measures, National competition authorities (NCAs), Patent settlements, Spain

(Universidad CEU San Pablo)/ /Leave a comment

On 21 October 2022 the Spanish CNMC imposed a fine of 38.9 million EUR on MERCK SHARP & DOHME DE ESPAÑA, S.A. and its parent company MSD HUMAN HEALTH HOLDING, B.V. (hereafter jointly ‘MSD’) for abusive practices in the Spanish market of contraceptive rings. Their breach consisted in having made baseless court claims with the…

Dutch clause, European Union, Excessive pricing, Intellectual property (IP), International Law Talk, Merger control, Patent settlements, Pharmaceuticals, Podcast

(University of Vienna, Austria)/ /Leave a comment

We are happy to announce the new International Law Talk Podcast episode on EU competition law developments in the pharmaceutical sector. And this one is twice as good! Not only are we discussing both competition and IP issues, but I also interviewed two leading experts in the field: Michael Clancy and David Hull from Van…

European Court of Justice, Patent settlements, Pharmaceuticals, Restriction by object

, , , (White & Case) and (White & Case, Belgium)/ /Leave a comment

On 25 March 2021, the European Court of Justice (“ECJ”) dismissed all the appeals against the European Commission’s decision to fine Lundbeck and several other companies for entering into anti-competitive patent settlement agreements.1 The judgments largely repeat the position taken by the ECJ in its January 2020 Paroxetine judgment (see our alert). They notably confirm…

European Union, Patent settlements, Pharmaceuticals

/ /Leave a comment

Introduction Servier v. Commission (Case T‑691/14) is the second decision of the General Court of the European Union on “pay-for-delay” patent settlements in the pharmaceutical industry,[1] following the 2016 decision of the Court on Lundbeck v. Commission (Case T-472/13).[2] In 2014, the European Commission imposed fines totalling €427.7 million for violations of European competition laws…

European Union, Patent settlements

, (Sidley Austin LLP)/ /Leave a comment

In a much-anticipated series of judgments, running to some 579 pages, the EU’s General Court on 8 September 2016 upheld a 2013 decision of the European Commission that imposed fines of almost €150 million on the innovative pharmaceutical manufacturer, Lundbeck, and a number of generic manufacturers with whom Lundbeck had entered into agreements to settle…